Methods of treating inflammatory conditions
View Patent ↗The present invention provides methods of treating a β-arrestin2 mediated and/or GPR120 mediated response in a subject. The β-arrestin2 mediated and/or GPR120 mediated response can be inflammation, including diabetes, inflammation associated with obesity and obesity. The methods can comprise administering to a subject a therapeutically effective amount of a compound predicted to bind a β-arrestin2 molecule and/or GPR120, wherein the compound selectively activates a β-arrestin2-dependent signaling pathway of GPR120.
1. A method of treating inflammation in a subject, the method comprising administering a therapeutically effective amount of a compound that binds GPR120, the compound selectively activating a β-arrestin2-dependent signaling pathway of GPR120.
2. The method of claim 1 , wherein the compound that selectively activates a β-arrestin2-dependent signaling pathway is an ω-3 fatty acid.
3. The method of claim 2 , wherein the ω-3 FA is DHA.
4. The method of claim 2 , wherein the ω-3 FA is EPA.
5. The method of claim 1 , wherein the compound selectively activates a β-arrestin2-dependent signaling pathway and does not activate a β-arrestin1-dependent signaling pathway.
6. The method of claim 1 , wherein the inflammation is associated with diabetes.
7. The method of claim 1 , wherein the inflammation is associated with obesity.
8. The method of claim 1 , wherein the subject is a human.
9. A method of treating an inflammatory condition associated with β-arrestin2 function, the method comprising administering a therapeutically effective amount of a β-arrestin2 modulating agent to a subject in need thereof.
10. The method of claim 9 , wherein the inflammatory condition is diabetes.
11. The method of claim 9 , wherein the inflammatory condition is associated with obesity.
12. The method of claim 9 , wherein the β-arrestin2 modulating agent is an ω-3 fatty acid.
13. The method of claim 9 , wherein the ω-3 fatty acid is DHA.
14. The method of claim 9 , wherein the ω-3 fatty acid is EPA.
15. The method of claim 9 , wherein the compound selectively activates a β-arrestin2-dependent signaling pathway and does not activate a β-arrestin2-dependent signaling pathway.
16. The method of claim 9 , wherein the subject is a human.